查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球濕性老齡化黃斑部病變(Wet AMD) 市場：按治療類型和地區分析和預測（2025-2035 年）
市場調查報告書
商品編碼
1734251

全球濕性老齡化黃斑部病變(Wet AMD) 市場：按治療類型和地區分析和預測（2025-2035 年）

Wet Age-Related Macular Degeneration (Wet AMD) Market - A Global and Regional Analysis: Focus on Treatment Type, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

由於老年人口的增加、人們對該疾病的認知的提高以及治療方法的進步，全球濕性老齡化黃斑部病變市場正在經歷強勁成長。

濕性老齡化黃斑部病變病變的主要治療方法包括抗VEGF（血管內皮生長因子）療法、動態療法（PDT）和雷射手術，其中抗VEGF藥物因其在預防或減緩疾病進展方面的有效性而佔據最大的市場佔有率佔有率。

該市場最重要的成長要素是全球人口老化。隨著人們壽命的延長，包括老齡化老齡化黃斑部病變部病變在內的老年性眼科疾病的發生率也在增加。老齡化黃斑部病變在65歲及以上人口中特別常見，隨著老齡人口的增加，尤其是已開發國家，濕性老齡化黃斑部病變患者的數量也在增加。聯合國預測，80歲及以上人口將從2019年的1.43億增加到2050年的4.26億，預計將增加需要治療黃斑部病變的患者人數。

光同調斷層掃瞄(OCT) 和眼底照相等技術的進步大大提高了我們早期檢測濕性老齡化黃斑部病變的能力。早期診斷的能力可以及時干預，以減緩疾病進展並改善患者的預後。診所和醫院擴大採用這些先進的診斷設備，可以幫助識別需要抗 VEGF 治療和其他治療的患者，從而推動市場成長。

隨著濕性老齡化市場不斷發展，長效治療方法的開發、採用人工智慧早期檢測等先進診斷技術以及對個人化醫療日益成長的興趣黃斑部病變新趨勢預計將決定未來的市場方向。對更實惠、更有效、更容易獲得的治療方法的需求不斷成長，特別是在醫療基礎設施不發達的地區，預計將為市場擴張創造巨大的機會。

本報告調查了全球濕性老齡化性黃斑部病變市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章 全球濕性老齡化黃斑部病變市場：產業展望

  • 市場趨勢
  • 法律規範
  • 流行病學
  • 臨床試驗分析
  • 市場動態
    • 影響分析
    • 市場促進因素
    • 市場挑戰
    • 市場機會

第2章 全球濕性老齡化黃斑部病變市場（依治療類型分類）

  • 抗VEGF治療
  • 基因治療
  • 其他

第3章 全球濕性老齡化黃斑部病變市場（按地區）

  • 北美洲
  • 歐洲
  • 亞太地區
    • 主要發現
    • 市場動態
    • 市場規模及預測

第4章全球濕性老齡化黃斑部病變市場：競爭格局與公司概況

  • 各公司主要策略及發展
    • 資金籌措活動
    • M&A
    • 監管部門核准
    • 夥伴關係、合作和業務擴展
  • 公司簡介
    • Regeneron Pharmaceuticals Inc
    • Ophthotech Corporation
    • Adverum Biotechnologies Inc
    • Apellis Pharmeceuticals Inc
    • Kubota Pharmaceutical Holdings Co. Ltd.
    • Pfizer Inc.
    • Novartis AG

第5章調查方法

Product Code: BHL2882SA

Global Wet Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035

Wet age-related macular degeneration is a progressive eye disease that is a leading cause of vision loss in individuals over the age of 50. It occurs when abnormal blood vessels grow under the retina, leaking fluid and causing damage to the macula, which is responsible for central vision. The condition severely affects the ability to read, recognize faces, and perform other tasks that require sharp vision. Wet age-related macular degeneration represents a major challenge for healthcare systems globally, as it significantly impacts the quality of life and imposes a high burden on individuals and economies.

The global wet age-related macular degeneration market is experiencing robust growth, driven by an aging population, increasing awareness about the condition, and advancements in treatment options. Key therapeutic approaches for wet age-related macular degeneration include anti-VEGF (vascular endothelial growth factor) therapies, photodynamic therapy, and laser surgeries, with the anti-VEGF drugs holding the largest market share due to their proven efficacy in halting or slowing disease progression. Furthermore, emerging treatments, including cell and gene therapy and stem cell therapy, are gaining attention as potential future solutions.

The most significant driver for the wet age-related macular degeneration market is the aging global population. As people live longer, the incidence of age-related eye conditions, including wet age-related macular degeneration, increases. Age-related macular degeneration is most common in individuals aged 65 and older, and as the world's elderly population continues to grow, particularly in developed nations, the number of wet age-related macular degeneration cases rises. The UN projects that the number of people aged 80 and older will increase from 143 million in 2019 to 426 million by 2050, leading to a larger patient pool for wet age-related macular degeneration treatments.

Technologies such as optical coherence tomography (OCT) and fundus photography have greatly enhanced the ability to detect wet age-related macular degeneration at an early stage. Early diagnosis allows for timely intervention, helping to slow disease progression and improve patient outcomes. The adoption of advanced diagnostic tools in clinics and hospitals is driving market growth by enabling healthcare providers to identify patients who would benefit from anti-VEGF therapies or other treatments.

The wet age-related macular degeneration market is indeed growing due to increasing awareness, technological advances in treatments, and an aging global population. However, the combination of high treatment costs, side effects, limited access to care, and the ongoing challenge of offering curative treatments are significant factors restricting the market's potential. Companies in the sector need to focus on reducing the cost of treatment, improving patient adherence, and advancing research to provide long-term and potentially curative therapies for Wet AMD. Addressing these challenges will be key to unlocking the market's full growth potential.

Some of the major players in the global wet age-related macular degeneration market, such as Regeneron Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, and Adverum Biotechnologies Inc., are continuously innovating to improve the effectiveness and comfort of wet age-related macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of wet age-related macular degeneration while enhancing their market positions globally.

The competitive landscape of the global wet age-related macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the wet age-related macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.

Market Segmentation:

Segmentation 1: by Treatment Type

  • Anti-VEGF Therapies
  • Gene Therapy
  • Others

Segmentation 2: by Region

  • North America
  • Europe
  • Asia-Pacific

As the wet age-related macular degeneration market continues to evolve, emerging trends such as the development of long-acting therapies, the integration of advanced diagnostic technologies like artificial intelligence (AI) for early detection, and the increasing focus on personalized medicine will shape its future trajectory. The growing demand for more affordable, effective, and accessible wet age-related macular degeneration treatments, particularly in underserved regions with limited healthcare infrastructure, will create significant opportunities for market expansion.

In conclusion, the global wet age-related macular degeneration market is on track for continued growth, driven by the aging population, increasing awareness of wet age-related macular degeneration, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for wet age-related macular degeneration solutions rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving the quality of life for people living with incontinence.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Wet Age-Related Macular Degeneration Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology of Wet Age-Related Macular Degeneration
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Wet Age-Related Macular Degeneration Market, by Treatment Type, $Million, 2023-2035

  • 2.1 Anti-VEGF Therapies
  • 2.2 Gene Therapy
  • 2.3 Others

3. Global Wet Age-Related Macular Degeneration Market, by Region, $Million, 2023-2035

  • 3.1 North America
    • 3.1.1 Key Findings
    • 3.1.2 Market Dynamics
    • 3.1.3 Market Sizing and Forecast
      • 3.1.3.1 North America Wet Age-Related Macular Degeneration Market, by Country
        • 3.1.3.1.1 U.S.
  • 3.2 Europe
    • 3.2.1 Key Findings
    • 3.2.2 Market Dynamics
    • 3.2.3 Market Sizing and Forecast
      • 3.2.3.1 Europe Wet Age-Related Macular Degeneration Market, by Country
        • 3.2.3.1.1 Germany
        • 3.2.3.1.2 U.K.
        • 3.2.3.1.3 France
        • 3.2.3.1.4 Italy
        • 3.2.3.1.5 Spain
  • 3.3 Asia Pacific
    • 3.3.1 Key Findings
    • 3.3.2 Market Dynamics
    • 3.3.3 Market Sizing and Forecast
      • 3.3.3.1 Asia Pacific Wet Age-Related Macular Degeneration Market, by Country
        • 3.3.3.1.1 Japan

4. Global Wet Age-Related Macular Degeneration Market: Competitive Landscape and Company Profiles

  • 4.1 Key Strategies and Developments by Company
    • 4.1.1 Funding Activities
    • 4.1.2 Mergers and Acquisitions
    • 4.1.3 Regulatory Approvals
    • 4.1.4 Partnerships, Collaborations and Business Expansions
  • 4.2 Company Profiles
    • 4.2.1 Regeneron Pharmaceuticals Inc
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products / Product Portfolio
      • 4.2.1.3 Target Customers/End-Users
      • 4.2.1.4 Key Personnel
      • 4.2.1.5 Analyst View
    • 4.2.2 Ophthotech Corporation
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products / Product Portfolio
      • 4.2.2.3 Target Customers/End-Users
      • 4.2.2.4 Key Personnel
      • 4.2.2.5 Analyst View
    • 4.2.3 Adverum Biotechnologies Inc
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products / Product Portfolio
      • 4.2.3.3 Target Customers/End-Users
      • 4.2.3.4 Key Personnel
      • 4.2.3.5 Analyst View
    • 4.2.4 Apellis Pharmeceuticals Inc
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products / Product Portfolio
      • 4.2.4.3 Target Customers/End-Users
      • 4.2.4.4 Key Personnel
      • 4.2.4.5 Analyst View
    • 4.2.5 Kubota Pharmaceutical Holdings Co. Ltd.
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products / Product Portfolio
      • 4.2.5.3 Target Customers/End-Users
      • 4.2.5.4 Key Personnel
      • 4.2.5.5 Analyst View
    • 4.2.6 Pfizer Inc.
      • 4.2.6.1 Overview
      • 4.2.6.2 Top Products / Product Portfolio
      • 4.2.6.3 Target Customers/End-Users
      • 4.2.6.4 Key Personnel
      • 4.2.6.5 Analyst View
    • 4.2.7 Novartis AG
      • 4.2.7.1 Overview
      • 4.2.7.2 Top Products / Product Portfolio
      • 4.2.7.3 Target Customers/End-Users
      • 4.2.7.4 Key Personnel
      • 4.2.7.5 Analyst View

5. Research Methodology

List of Figures

  • Figure: Global Wet Age-Related Macular Degeneration Market, Dynamics Impact Analysis
  • Figure: Epidemiology of Wet Age-Related Macular Degeneration
  • Figure: Global Wet Age-Related Macular Degeneration Market Coverage
  • Figure: Global Wet Age-Related Macular Degeneration Market Key Trends, Impact Analysis, 2023-2035
  • Figure: Global Wet Age-Related Macular Degeneration Market, Competitive Landscape, January 2022-April 2025

List of Tables

  • Table: Global Wet Age-Related Macular Degeneration Market, Clinical Trial Analysis,
  • Table: Global Wet Age-Related Macular Degeneration Market Dynamics, Impact Analysis
  • Table: Global Wet Age-Related Macular Degeneration Market (by Treatmet Type), $Million, 2023-2035
  • Table: Global Wet Age-Related Macular Degeneration Market (by Region), $Million, 2023-2035